SAN DIEGO, April 1, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil will be sponsoring TEAbraco 2019 International Autism Week from April 1 to April 7 at the Iguatemi Mall in Ribeirão Preto, Brazil.
"As a company, we see events like this one as prime opportunities to educate the people of Brazil about the history of medical cannabis, the difference between hemp and marijuana and our cannabidiol (CBD) products and their potential benefits," said HempMeds® Vice President Caroline Heinz. "In Brazil, CBD is legal to be imported and is even subsidized by the Brazilian Government for several indications including autism. We hope to inform people at the event of this because even though legislation passed a few years ago, there are still many citizens who don't know that they may already be eligible to receive CBD at no cost."
In addition to sponsoring the event, HempMeds® Brasil will host an educational seminar on April 4 from 6:30 p.m. to 10:00 p.m. where attendees can learn about the medical cannabis market in Brazil, how CBD interacts with the body and the global landscape of medical cannabis. Executives such as HempMeds® Director of Medical Affairs Junior Gibelli, Endocannabinoid System Researcher Dr. Aliane Araujo, Neurologist Dr. Paula Vinha and Neuropediatician at the Albert Einstein Hospital Dr. Abram Topczewski will be presenting as well as taking questions from attendees.
On April 5, HempMeds® Brasil will host a CBD workshop lead by child psychiatrist Dr. Murielle Moura, who has a background in treating autism and other neurodevelopment disorders, for researchers and doctors to learn about how CBD interacts with the brain. The event will feature other workshops on April 5-6 with top international speakers and more than 400 lectures.
"Our Brazilian subsidiary is very active in the medical and scientific communities and has a strong background in providing the education citizens need to understand how to incorporate medical cannabis into their lives and professions," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Medical Marijuana, Inc. is very proud to be the first U.S. company to legally export CBD products to Brazil and, as evidenced by the company's participation in this event, plans to continue to be a leader in the Brazilian medical cannabis industry."
TEAbraco 2019 International Autism Week will feature a well-rounded program of art exhibitions, free lectures given by top professionals and experts, presentations and demonstrations from scientific and medical researchers and training courses aimed at providing tools that families living with autism could use to improve their everyday lives.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson's, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications. www.hempmeds.com.br.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
SOURCE Medical Marijuana, Inc.